GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bone Biologics Corp (NAS:BBLG) » Definitions » EV-to-FCF

Bone Biologics (Bone Biologics) EV-to-FCF : 0.17 (As of May. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Bone Biologics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bone Biologics's Enterprise Value is $-1.58 Mil. Bone Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.51 Mil. Therefore, Bone Biologics's EV-to-FCF for today is 0.17.

The historical rank and industry rank for Bone Biologics's EV-to-FCF or its related term are showing as below:

BBLG' s EV-to-FCF Range Over the Past 10 Years
Min: -252.19   Med: 0   Max: 0.7
Current: 0.17

During the past 10 years, the highest EV-to-FCF of Bone Biologics was 0.70. The lowest was -252.19. And the median was 0.00.

BBLG's EV-to-FCF is ranked better than
96.4% of 361 companies
in the Medical Devices & Instruments industry
Industry Median: 28.78 vs BBLG: 0.17

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), Bone Biologics's stock price is $1.50. Bone Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-22.611. Therefore, Bone Biologics's PE Ratio for today is At Loss.


Bone Biologics EV-to-FCF Historical Data

The historical data trend for Bone Biologics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bone Biologics EV-to-FCF Chart

Bone Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -41.23 -566.40 -24.22 1.21 0.06

Bone Biologics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.34 0.23 0.06 0.11

Competitive Comparison of Bone Biologics's EV-to-FCF

For the Medical Devices subindustry, Bone Biologics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bone Biologics's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bone Biologics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Bone Biologics's EV-to-FCF falls into.



Bone Biologics EV-to-FCF Calculation

Bone Biologics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-1.577/-9.509
=0.17

Bone Biologics's current Enterprise Value is $-1.58 Mil.
Bone Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bone Biologics  (NAS:BBLG) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Bone Biologics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.50/-22.611
=At Loss

Bone Biologics's share price for today is $1.50.
Bone Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.611.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Bone Biologics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Bone Biologics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Bone Biologics (Bone Biologics) Business Description

Traded in Other Exchanges
N/A
Address
2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Executives
Deina H Walsh officer: Chief Financial Officer 175, MAY STREET, EDISON NJ 08837
Jeff Frelick officer: Chief Operating Officer 1 FOX RUN LANE,, LEXINGTON MA 02420
Knight Insurance Company, Ltd 10 percent owner 4751 WILSHIRE BLVD.,, SUITE 111, LOS ANGELES CA 90010
Siddhesh Rajendra Angle director 481 MONMOUTH ST, UNIT G,, JERSEY CITY NJ 07302
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Don Hankey director, 10 percent owner, officer: Chairman of the Board 4751 WILSHIRE BLVD., SUITE 110, LOS ANGELES CA 90010
Bret Hankey director 4751 WILSHIRE BLVD. #110, LOS ANGELES CA 90010
Hankey Capital, Llc 10 percent owner 4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Don Hankey Trust 10 percent owner 4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Amir F Heshmatpour 10 percent owner 269 S. BEVERLY DRIVE, STE #1600, BEVERLY HILLS CA 90212
Musculoskeletal Transplant Foundation, Inc. director 175 MAY STREET, SUITE 300, EDISON NJ 08837
Benjamin Wu director 2740 LORAIN ROAD, SAN MARINO CA 91108
La Neve Stephen R. director, officer: CEO and President 106 MCCOOL BLVD, WEST CHESTER PA 19380
George A Oram director 12 EDGEMONT LANE, BEDMINSTER NJ 07921
Jim Delshad director 132 S. MAPLE DR., BEVERLY HILLS CA 90212